Growth Hormone Therapy Improves Cardiometabolic Risk Markers in Girls With Turner Syndrome: Findings From the Korean OUTSPREAD Cohort
Using data from the nationwide Korean OUTSPREAD cohort, this study demonstrates that growth hormone therapy in girls with Turner syndrome not only improves height without increasing BMI but also attenuates the worsening of total cholesterol and improves other lipid profiles, supporting its cardiometabolic safety and potential benefits.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Turner syndrome is a condition that affects girls and women when one of their two X chromosomes is missing or altered. While the most visible sign is often short stature, the condition carries a hidden burden: a higher risk for heart and metabolic problems later in life. Girls with this syndrome are more likely to develop high cholesterol, fatty liver, and issues with how their bodies handle sugar, which can lead to heart disease and stroke at a younger age than in the general population. To help them grow taller, doctors frequently prescribe human growth hormone, a treatment that has been standard care for decades. However, a lingering question has remained for the medical community: does this treatment, while helping children reach a normal height, accidentally make their hearts or livers work harder? For years, scientists have debated whether the hormone simply does its job on height without touching the rest of the body, or if it might quietly shift the balance of fats and sugars in ways that could be harmful.
A large team of researchers across South Korea decided to settle this question by looking at real-world data from hundreds of girls over many years. They gathered information from thirty different hospitals, tracking the health of 116 girls with Turner syndrome. About eighty-three percent of these girls received growth hormone treatment, while the rest did not, serving as a comparison group to see what happens naturally without the medication. The researchers did not just look at how tall the girls grew; they meticulously measured their blood chemistry, paying close attention to the types of cholesterol that clog arteries, the enzymes that signal liver stress, and the levels of sugar in their blood. They followed these girls for an average of nearly ten years, allowing them to see how the body changes over a long stretch of time rather than just a few months.
The results of this long-term observation offer a reassuring picture. The girls who received growth hormone therapy grew significantly taller, improving their height relative to their age, without gaining excess weight. More importantly, their blood profiles showed signs of protection rather than harm. In the group that did not receive treatment, total cholesterol levels rose noticeably over the decade, a trend that suggests a natural worsening of heart risk factors as these girls aged. In contrast, the girls treated with growth hormone saw their total cholesterol levels stay steady. Even more encouraging, the treated group saw their "good" cholesterol rise and their "bad" cholesterol fall. This shift suggests that the treatment may actually help clear the arteries of fatty deposits, rather than clogging them.
The study also looked at the liver, an organ that often struggles in girls with Turner syndrome, sometimes showing signs of fatty buildup or inflammation. The researchers found that the liver enzymes, which act as warning lights for liver stress, dropped significantly in the treated group. While the untreated group also saw some improvement in one type of liver enzyme, the drop in the other, more specific marker happened only in the girls receiving the hormone. This points to a potential benefit where the treatment helps the liver process fats more efficiently. Regarding blood sugar, the treatment did not cause the dangerous spikes in insulin or sugar levels that some earlier, shorter studies had worried about. While a small, normal rise in a long-term sugar marker was seen in both groups as they aged, the treated girls remained well within the healthy range, and the hormone was not found to be the cause of any worsening in sugar control.
By comparing the two groups side by side and adjusting for other factors like age and the use of other medications, the researchers concluded that growth hormone therapy is safe for the heart and liver in the long run. The data suggests that the treatment does more than just add inches to a child's height; it appears to help maintain a healthier balance of fats in the blood and keep the liver functioning smoothly. While the study cannot guarantee that every single girl will have the same experience, the findings provide strong evidence that this standard treatment does not carry the hidden metabolic risks that some had feared. Instead, it supports the idea that growth hormone is a vital part of care that helps these girls grow tall while keeping their internal systems running safely as they move into adulthood.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.